Representing Patient Voices \ 2023
Brain Cancer Canada provided an account of the patient and caregiver experience to The Formulary Management Expert Committee (FMEC), of the Canadian Agency for Drugs, Technology, and Health (CADTH), now Canada Drug Agency (CDA), during a reimbursement review for the concurrent use of Lomustine and Bevacizumab, two front-line chemotherapies.
Collaborative Advocacy for Access to Treatment \ 2024
Brain Cancer Canada led a 5-agency collaborative advocacy campaign addressed to the Canadian Association of Provincial Cancer Agencies (CAPCA) advocating for the expansion of access to drugs and therapies for patients with Glioblastoma.
A National Call for Brain Cancer Research \ 2024
Tammy Farand, a brain cancer advocate from St. Albert, Alberta, with support from Member of Parliament M. Cooper, launches a national brain cancer research petition.